Trial Profile
A Double-Blind, Placebo Controlled, Gluten Challenge Trial of the Efficacy, Safety and Tolerability of 6-weeks Treatment of Latiglutenase (IMGX003) Administration in Patients With Well-Controlled Celiac Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Acronyms CeliacShield
- Sponsors ImmunogenX
- 15 Aug 2022 Results published in the CEL-SCI Corporation Media Release.
- 02 Aug 2022 Results published in the Gastroenterology
- 18 Mar 2021 Results presented in an ImmunogenX Media Release.